Improved survival rates found for babies with severe fetal disorders

A groundbreaking clinical trial has revealed a promising prenatal treatment for fetuses diagnosed with anhydramnios, a devastating condition characterized by the absence of sufficient amniotic fluid due to fetal kidney failure. Historically, such diagnoses offered almost no hope of postnatal survival. However, the federally funded Renal Anhydramnios Fetal Therapy (RAFT) trial, spearheaded by the Johns Hopkins Center for Fetal Therapy and Johns Hopkins Children’s Center, has demonstrated that serial amnioinfusions combined with postnatal dialysis can enable some affected infants to survive and thrive into toddlerhood.

Amniotic fluid, primarily produced as fetal urine by the 16 to 20-week gestation mark, is vital for lung development as it delivers critical nutrients, hormones, and growth factors. Anhydramnios typically arises from major malformations such as bilateral renal agenesis or urinary tract obstructions, which prevent urine production or excretion, leading to near-complete absence of amniotic fluid. Without this fluid, fetuses face severe pulmonary hypoplasia, rendering respiratory function insufficient at birth and historically resulting in neonatal mortality.

In the RAFT trial, 32 pregnant women carrying fetuses with renal failure underwent repeated amnioinfusions before 26 weeks of gestation. These infusions involved injecting fluid mimicking natural amniotic fluid directly into the womb to compensate for the deficient endogenous fluid, aiming to stimulate lung growth. More than 90% of these pregnancies resulted in premature births before 37 weeks, with roughly two-thirds of newborns surviving beyond two weeks post-delivery. These infants were then able to receive surgical access for dialysis, providing a vital bridge for kidney replacement therapy after birth.

Dr. Meredith Atkinson, a pediatric nephrologist and co-lead investigator, emphasized the critical role of amniotic fluid in lung maturation and the potential of prenatal intervention to alter outcomes previously deemed impossible. The study not only underscores the feasibility and safety of amnioinfusions in this context but also marks a major advance in fetal therapy for renal failure-related anhydramnios.

While encouraging, the research also highlights ongoing challenges. Prematurity remains a significant complication, and infants often confront complex medical hurdles beyond lung function. The RAFT investigators plan to launch a subsequent study phase focusing on strategies to prolong gestation closer to full term, thereby improving neonatal resilience to chronic dialysis and related treatments.

The RAFT trial exemplifies the power of multidisciplinary collaboration across 13 U.S. medical centers. It also invites hope for families facing dire prenatal diagnoses, with patients like Levi Smith, now two years old and thriving with chronic dialysis, personifying the therapeutic potential. This innovative approach paves the way toward a paradigm shift in managing fetal renal failure and offers a beacon of hope where none existed before.